Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 3/2012

Open Access 01-09-2012 | Meeting abstract

Regulatory natural autoantibodies suppress inflammation and SLE disease activity

Authors: GJ Silverman, J Vas, C Grönwall

Published in: Arthritis Research & Therapy | Special Issue 3/2012

Login to get access

Excerpt

Our recent studies have shown that IgM natural antibodies (NAbs) that recognize epitopes on apoptotic cells (ACs) are present from birth and can have potent immunoregulatory properties. These antibodies, by recruiting early complement recognition factors, C1q or mannose-binding lectin, enhance AC clearance by innate immune cells and also mediate suppression of proinflammatory responses induced by Toll-like receptor (TLR) agonists [1, 2]. Furthermore, in vivo administration blocks the development of inflammatory autoimmune disease in experimental murine models [2]. We therefore explored the mechanistic basis for these properties and assessed for potential clinical relevance. …
Literature
1.
Chen YF, Park YB, Patel E, Silverman GJ: IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells. J Immunol. 2007, 182: 6031-6043.CrossRef
2.
Chen Y, Khanna S, Goodyear CS, Park YB, Raz E, Thiel S, Grönwall C, Vas J, Boyle DL, Corr M, Kono DH, Silverman GJ: Regulation of dendritic cells and macrophages by an anti-apoptotic-cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J Immunol. 2007, 183: 1346-1359.CrossRef
3.
Vas J, Grönwall C, Marshak-Rothstein A, Silverman GJ: Natural autoantibody to apoptotic cell membranes inhibits the stimulatory properties of lupus autoantibody immune complexes. Arthritis Rheum. 2012, doi: 10.1002/art.34537,
4.
Grönwall C, Akhter E, Oh C, Burlingame RW, Petri M, Silverman GJ: IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE. Clin Immunol. 2012, 142: 390-398. 10.1016/j.clim.2012.01.002.PubMedCentralCrossRefPubMed
Metadata
Title
Regulatory natural autoantibodies suppress inflammation and SLE disease activity
Authors
GJ Silverman
J Vas
C Grönwall
Publication date
01-09-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 3/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3961

Other articles of this Special Issue 3/2012

Arthritis Research & Therapy 3/2012 Go to the issue

Meeting abstract

Genetic-epigenetic interaction in lupus

Meeting abstract

Hopkins Lupus Cohort: assessment of treatment effects

Meeting abstract

Complement deficiencies and susceptibility to systemic lupus erythematosus revisited

Meeting abstract

Renal flare as a biomarker of incident and progressive chronic kidney disease in patients with lupus nephritis

Meeting abstract

Differing environmental risk factors for membranous versus proliferative lupus nephritis

Meeting abstract

Rising prevalence of systemic autoimmune rheumatic disease: increased awareness, increased disease or increased survival?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits